文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

人工智能时代的药物警戒:进展、挑战与思考

Pharmacovigilance in the Era of Artificial Intelligence: Advancements, Challenges, and Considerations.

作者信息

Rudnisky Eli, Paudel Keshab

机构信息

Biomedical Sciences, Burrell College of Osteopathic Medicine, Melbourne, USA.

出版信息

Cureus. 2025 Jun 29;17(6):e86972. doi: 10.7759/cureus.86972. eCollection 2025 Jun.


DOI:10.7759/cureus.86972
PMID:40734859
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12306650/
Abstract

Pharmacovigilance (PV) is a science that plays a crucial role in protecting patients by detecting adverse drug reactions (ADRs). PV can do this by collecting and analyzing data from a wide variety of healthcare sources. However, traditional PV methods face limitations, particularly in accurately and efficiently analyzing large datasets. This limitation leads to underreported ADRs, which negatively impact many patients. However, with the recent rise in artificial intelligence, PV as a science has the potential to improve. This can be done by incorporating different subsets of AI, such as machine learning (ML) and natural language processing (NLP), into PV. The aim of this study is to describe how integrating AI, specifically ML and NLP, into PV systems can improve data collection, data processing, and the detection of ADRs. A comprehensive literature search was conducted using PubMed and Google Scholar to examine studies that were conducted within the last 30 years. Twenty-eight studies were included in this paper. Inclusion criteria included articles that were written in English, articles focusing on PV as a science, ADRs, AI's current role in PV, and AI's potential role in PV. Exclusion criteria included studies that were not published in English and studies that were published more than 30 years ago. The findings from several systematic reviews that explore the implementation of AI into PV indicate that AI can improve PV by enhancing the efficiency and accuracy of detecting ADRs. Through ML algorithms, ADRs can be identified more quickly and accurately compared to traditional PV methods; while using the NLP model, AI is able to extract relevant patient data from unstructured data sources such as electronic health records (EHRs) and report certain drug interactions more accurately and efficiently. However, there are limitations to incorporating AI into PV. These include ethical, legal, and privacy concerns; interpretative limitations if certain datasets are incomplete and are missing information; the lack of current research; and the need to conduct more research on this topic to definitively determine whether AI should be incorporated into PV. With the exponential development of technology such as AI, there is a lot of promise in strengthening PV into a more accurate and efficient ADR detection system. While there is some research highlighting AI's potential to enhance PV, much more research needs to be conducted to fully substantiate this claim. Incorporating AI into PV does, however, have the potential to change ADR detection methods for the better.

摘要

药物警戒(PV)是一门通过检测药物不良反应(ADR)来保护患者的科学。PV可以通过收集和分析来自各种医疗保健来源的数据来实现这一点。然而,传统的PV方法面临局限性,特别是在准确有效地分析大型数据集方面。这种局限性导致ADR报告不足,对许多患者产生负面影响。然而,随着人工智能最近的兴起,作为一门科学的PV有改进的潜力。这可以通过将人工智能的不同子集,如机器学习(ML)和自然语言处理(NLP),纳入PV来实现。本研究的目的是描述将人工智能,特别是ML和NLP,集成到PV系统中如何能够改善数据收集、数据处理以及ADR的检测。使用PubMed和谷歌学术进行了全面的文献检索,以审查过去30年内进行的研究。本文纳入了28项研究。纳入标准包括用英语撰写的文章、专注于作为一门科学的PV的文章、ADR、人工智能在PV中的当前作用以及人工智能在PV中的潜在作用。排除标准包括非英语发表的研究以及30多年前发表的研究。几项探索将人工智能应用于PV的系统评价结果表明,人工智能可以通过提高检测ADR的效率和准确性来改善PV。通过ML算法,与传统的PV方法相比,可以更快、更准确地识别ADR;而使用NLP模型,人工智能能够从电子健康记录(EHR)等非结构化数据源中提取相关患者数据,并更准确、高效地报告某些药物相互作用。然而,将人工智能纳入PV也存在局限性。这些包括伦理、法律和隐私问题;如果某些数据集不完整且缺少信息,则存在解释局限性;目前研究的缺乏;以及需要对该主题进行更多研究,以最终确定是否应将人工智能纳入PV。随着人工智能等技术的指数级发展,将PV强化为一个更准确、高效的ADR检测系统有很大的前景。虽然有一些研究强调了人工智能增强PV的潜力,但需要进行更多研究来充分证实这一说法。然而,将人工智能纳入PV确实有可能更好地改变ADR检测方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8070/12306650/9202aee64773/cureus-0017-00000086972-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8070/12306650/9202aee64773/cureus-0017-00000086972-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8070/12306650/9202aee64773/cureus-0017-00000086972-i01.jpg

相似文献

[1]
Pharmacovigilance in the Era of Artificial Intelligence: Advancements, Challenges, and Considerations.

Cureus. 2025-6-29

[2]
Short-Term Memory Impairment

2025-1

[3]
Sexual Harassment and Prevention Training

2025-1

[4]
Eliciting adverse effects data from participants in clinical trials.

Cochrane Database Syst Rev. 2018-1-16

[5]
The Black Book of Psychotropic Dosing and Monitoring.

Psychopharmacol Bull. 2024-7-8

[6]
Home treatment for mental health problems: a systematic review.

Health Technol Assess. 2001

[7]
The Lived Experience of Autistic Adults in Employment: A Systematic Search and Synthesis.

Autism Adulthood. 2024-12-2

[8]
Health professionals' experience of teamwork education in acute hospital settings: a systematic review of qualitative literature.

JBI Database System Rev Implement Rep. 2016-4

[9]
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].

Epidemiol Prev. 2013

[10]
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.

Cochrane Database Syst Rev. 2022-5-20

本文引用的文献

[1]
Artificial intelligence (AI) in pharmacovigilance: A systematic review on predicting adverse drug reactions (ADR) in hospitalized patients.

Res Social Adm Pharm. 2025-6

[2]
Applying AI to Structured Real-World Data for Pharmacovigilance Purposes: Scoping Review.

J Med Internet Res. 2024-12-30

[3]
Artificial intelligence in pharmacovigilance - Opportunities and challenges.

Perspect Clin Res. 2024

[4]
A Pilot, Predictive Surveillance Model in Pharmacovigilance Using Machine Learning Approaches.

Adv Ther. 2024-6

[5]
Navigating duplication in pharmacovigilance databases: a scoping review.

BMJ Open. 2024-4-29

[6]
Extracting adverse drug events from clinical Notes: A systematic review of approaches used.

J Biomed Inform. 2024-3

[7]
Will the future of pharmacovigilance be more automated?

Expert Opin Drug Saf. 2023

[8]
Artificial Intelligence and Data Mining for the Pharmacovigilance of Drug-Drug Interactions.

Clin Ther. 2023-2

[9]
Adverse drug event detection using natural language processing: A scoping review of supervised learning methods.

PLoS One. 2023

[10]
Exploratory pharmacovigilance with machine learning in big patient data: A focused scoping review.

Basic Clin Pharmacol Toxicol. 2023-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索